In another open-label, multi-center, phase Ia/Ib study (NCT0198555) conducted in China in patients (n = 85) with advanced tumors bearing MET aberrations, savolitinib demonstrated a manageable safety profile and promising anti-tumor activity in NSCLC with METex14 mutation, apparent tumor shrinkage (55% and 27%) in target lesions was observed, although partial response (PR) was not achieved. This evidence concerns the gene MET and neoplasm.